Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

Trial Profile

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Dec 2018

At a glance

  • Drugs Crizotinib (Primary) ; Iobenguane (Primary) ; Aldesleukin; Busulfan; Carboplatin; Cisplatin; Cyclophosphamide; Dexrazoxane; Dinutuximab; Doxorubicin; Etoposide phosphate; Isotretinoin; Melphalan; Sargramostim; Thiotepa; Topotecan; Vincristine
  • Indications Neuroblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Dec 2018 Planned End Date changed from 28 Mar 2022 to 30 Jun 2026.
    • 12 Dec 2018 Planned primary completion date changed from 28 Mar 2022 to 30 Jun 2026.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top